Michael Penna is a Senior student pursuing a Bachelor's of Science in Finance and a Bachelor's of Science in Management Information Systems with a Minor in Economics. He joined FMA in 2019, and promptly became the analyst for the Financial Sector, as well as Secretary. Michael completed his Series 7 and Series 66 before his Junior year, and is currently studying for the CFA exam. This past summer, he completed an internship at Goldman Sachs, working in Private Wealth Management.
Thesis: We recommend selling EVBN due to their stagnant market share caused by fierce competition, escalating loan delinquencies, compressed net interest margins, decelerated mortgage growth, and substantial headwinds from the U.S. recession.
We are up 145.52% on TransMedics and given current market conditions, it makes sense to take profits while we can.
BUY 10 Shares of SDS for a 2x projected profit based on several catalysts, notably a second COVID-19 wave.